Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative Effectiveness of Racemic Ketamine vs Esketamine for Treatment-Resistant Depression
NCT06713616Phase 3Recruiting
- Sponsor
- Yale University
- Start
- Jan 2025
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ketamine in treatment-resistant depression (TRD), sponsored by Yale University. Started Jan 2025; status: recruiting.
02
Drugs
ketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT06713616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06713616.